Director, CEO and Chairman · NRX Pharmaceuticals, Inc. · NRX Pharmaceuticals, Inc. — Restricted Stock Unit
Side
A
Value
—
Shares
150.0K
Price
—
Executed
Jul 28, 2026
Disclosed
Nov 4, 2026
Disclosure timeline99 days from execution to publication · legal deadline 2 business days
Jul 28 executedNov 4, 2026 disclosed
NRXP · daily
Yahoo Finance chart API
◉This trade, on the day it was made▼Disclosure●Material company filing◯Other disclosed buy◯Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Grant or award — administrative, little informational value
Relative size+1 / 25
No reported dollar value · new position
Filing timing+15 / 15
Disclosed 71 business days after execution (deadline: 2)
Historical behavior+8 / 15
First recorded trade by this actor in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Javitt Jonathan C filed this Form 4 reporting a grant or award of NRXP on Jul 28, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, CEO and Chairman
Javitt Jonathan Ccik:0001303782
Issuer
NRX Pharmaceuticals, Inc.cik:0001719406
Revision history · 0
No field has changed since this record was first ingested.
